GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

RNS60

Company
Mario Negri Institute for Pharmacological Research
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Trial details
  • Completed NCT NCT01057498

    Safety Study of Nebulized RNS60 to Treat Asthma.

    Not yet reported Revalesio Corporation 36 participants Est. completion 2011-01 2 sites Stand-alone
    Other conditions: Asthma
    View official trial listing →
  • Completed NCT NCT01264783

    Safety and Tolerability of RNS60 Given by IV to Healthy Subjects

    Not yet reported Revalesio Corporation 12 participants Est. completion 2011-09 1 site Stand-alone
    Other conditions: Myocardial Infarct
    View official trial listing →
  • Completed NCT NCT01511302

    Study of Inhaled RNS60 in Combination With Budesonide to Treat Mild to Moderate Asthma

    Not yet reported Revalesio Corporation 65 participants Est. completion 2013-05 4 sites Stand-alone
    Other conditions: Asthma
    View official trial listing →
  • Withdrawn NCT NCT01714089

    Proof of Concept Study Evaluating RNS60 in the Treatment of Relapsing Remitting Multiple Sclerosis

    Not yet reported Revalesio Corporation 1 site Stand-alone
    Other conditions: Relapsing Remitting Multiple Sclerosis
    View official trial listing →
  • Withdrawn NCT NCT01922427

    Study of RNS60 on Pain and Function After Knee Anterior Cruciate Ligament Surgery

    Not yet reported Revalesio Corporation
    Other conditions: Anterior Cruciate Ligament Reconstruction
    View official trial listing →
  • Withdrawn NCT NCT02005523

    Study of RNS60 on Pain and Function After Hip Labral Repair

    Not yet reported Revalesio Corporation 1 site Stand-alone
    Other conditions: Hip Labral Tear
    View official trial listing →
  • Completed NCT NCT02422121

    Effect of RNS60 on the Late Phase Asthmatic Response to Allergen Challenge

    Not yet reported Revalesio Corporation 30 participants Est. completion 2015-11 1 site Stand-alone
    Other conditions: Asthma
    View official trial listing →
  • Completed NCT NCT02490865

    Systemic Bioactivity of Inhaled Nebulized RNS60

    Not yet reported Revalesio Corporation 56 participants Est. completion 2015-08 1 site Stand-alone
    Other conditions: Systemic Bioactivity of Nebulized RNS60
    View official trial listing →
  • Withdrawn NCT NCT02497222

    Pilot Study of RNS60 in Allergen-induced Bronchoconstriction

    Not yet reported Revalesio Corporation 1 site Stand-alone
    Other conditions: Asthma
    View official trial listing →
  • Completed NCT NCT02525471

    A Pilot Study of RNS60 in Amyotrophic Lateral Sclerosis (ALS)

    Not yet reported Sabrina Paganoni, M.D. 24 participants Est. completion 2017-10-18 1 site Stand-alone
    Other conditions: ALS
    View official trial listing →
  • Withdrawn NCT NCT02988297

    Nebulized RNS60 for the Treatment of Amyotrophic Lateral Sclerosis

    Not yet reported Revalesio Corporation Est. completion 2028-11 Stand-alone
    Other conditions: Amyotrophic Lateral Sclerosis
    View official trial listing →
  • Completed NCT NCT03456882

    The Effect of RNS60 on ALS Biomarkers

    Not yet reported Mario Negri Institute for Pharmacological Research 147 participants Est. completion 2021-05-30 23 sites
    Other conditions: Amyotrophic Lateral Sclerosis
    View official trial listing →
  • Completed NCT NCT04693715

    Safety of RNS60 in Large Vessel Occlusion Stroke Patients Undergoing Endovascular Thrombectomy

    Not yet reported Revalesio Corporation 83 participants Est. completion 2023-11-08 7 sites Stand-alone
    Cardiovascular disease
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.